Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.75, Implies 7% Upside

Myriad Genetics, Inc.'s average 12-month price target has been lowered to $5.75 from $6.14 by 8 analysts, suggesting a potential 7% upside from its July 30 closing price. The target range for the stock is between $4 and $10 per share. Despite the cut, the consensus rating from 9 analysts remains "Hold," with 2 Buys, 5 Holds, and 2 Sells.